Preparation and use methods of viroid cation ruthenium-based nanoparticles
By developing virus-like cationic ruthenium-based nanoparticles, the corneal crosslinking is achieved using nanoscale and adsorption-mediated effects to achieve efficient crosslinking in visible light, the problems of low permeability and insufficient crosslinking mechanism in the existing technology are solved, and non-invasiveness is achieved. Efficient keratoconus treatment.
Patent Information
- Application Number
- CN202411040703.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, when treating keratoconus, the permeability of riboflavin is low and requires long-term exposure of ultraviolet light, resulting in corneal damage and complications. The synergistic effect of ruthenium compounds and sodium persulfate is insufficient, which has failed to effectively solve the low permeability and intersection. The problem of linkage mechanisms and the use of nanoscale and biological topology to promote transcorneal epithelial efficiency.
Develop viral-like cationic ruthenium-based nanoparticles that efficiently penetrate into the corneal matrix under visible light through nanoscale and adsorption-mediated effects, utilizing the cross-linking of cationic ruthenium-based polymers with corneal glycoprotein and collagen fibers, combining ammonium persulfate and visible light Catalyzing the realization of a double cross-linking mechanism.
Non-invasive and efficient keratoconus treatment was achieved, improving the tightness and penetration efficiency of corneal cross-linking, and reducing the occurrence of postoperative complications.
Smart Images

Figure CN118976121A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for preparing and using virus-like cationic ruthenium-based nanoparticles for treating keratoconus. Background Art
[0002] Keratoconus is a common blinding eye disease in clinical practice, with 1 in every 400-2000 people suffering from keratoconus, and it is more common in young people. Riboflavin-based corneal epithelial collagen cross-linking is a promising treatment for keratoconus. It stimulates riboflavin to generate singlet oxygen or free radicals through ultraviolet light, and establishes covalent cross-linking bonds between functional groups with amino acid residues on collagen fibers. However, riboflavin has a low permeability to the corneal epithelial matrix. In order to avoid complications such as infection and corneal melting caused by scraping the corneal epithelium, cross-epithelial cross-linking can be achieved more efficiently by using a penetration enhancer. For example, Italian patent MI2007A002162 uses benzalkonium chloride as a penetration enhancer to allow riboflavin to penetrate into the corneal stroma to cross-link corneal collagen; CN102470120A proposes that amino acids, coenzyme Q, vitamin E, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine, and compounds for stimulating the production of metalloproteinase MMP9 can be used as penetration enhancers to form an ophthalmic solution with riboflavin-dextran solution to achieve trans-corneal epithelial cross-linking therapy. Keratoconus; CN102164592B discloses an enhancer that can be used with riboflavin, including EDTA combined with tromethamine, sodium EDTA combined with tromethamine, and potassium EDTA combined with tromethamine, used alone or in combination, to improve the absorption of riboflavin to improve the therapeutic effect of keratoconus; CN115177729B discloses an adrenergic receptor agonist as a cross-linking penetration enhancer for keratoconus, which can effectively promote the penetration of riboflavin into the corneal stroma. In addition, during the treatment process, the eyes need to be exposed to ultraviolet rays for a long time (about 30 minutes in total), which increases the risk of irreversible damage to the corneal epithelium and corneal edema, permanent corneal opacity, corneal endothelial failure and other postoperative complications. Therefore, a high-permeability cross-linking agent that can cross the corneal epithelium into the corneal stroma and does not rely on ultraviolet light-mediated cross-linking is of great significance for achieving non-invasive treatment of keratoconus.
[0003] The single electron transfer effect of ruthenium derivatives under visible light catalysis can effectively cross-link tyrosine groups in corneal glycoproteins or collagen fibers, and can be used as a substitute for riboflavin to become a promising drug for visible light-mediated cross-linking treatment of keratoconus. In addition, viruses have the most efficient transmembrane transport mechanism in nature due to their rich cell surface functional groups, topological structure and nanoscale. Virus-inspired virus-like nanoparticles (<100nm) are surface-modified to mimic the biological topological structure and surface interface functions of viruses, which is expected to promote the penetration of ruthenium derivatives into the corneal stroma. In addition, in view of the negative charge on the surface of corneal epithelial cells, nanoparticles with positive charges on the surface can further improve their trans-corneal epithelial delivery efficiency through adsorption-mediated effects. Therefore, the development of a virus-like cationic ruthenium-based nanoparticle with a positive charge on the surface as a high-penetration cross-linking agent is expected to achieve efficient trans-corneal epithelial cross-linking treatment of keratoconus under visible light.
[0004] In order to further explain the characteristics of the present invention, the applicant further conducted relevant searches and the following is a preliminary explanation:
[0005] Prior art WO2024054165A1 discloses a method and pharmaceutical composition for treating eye diseases by visible light-induced corneal cross-linking using a ruthenium compound, which comprises a therapeutically effective amount of a ruthenium compound and sodium persulfate; a pharmaceutically acceptable carrier;
[0006] WO2017095240A1 mentions that ruthenium and SPS (sodium persulfate) compounds are used together as photoinitiators for photopolymerization processes. The wavelength range used is between 400-700nm, more preferably 400-450nm. It is said that the method using visible light and a ruthenium-SPS mixture has less phototoxicity to cells and can be used for tissue engineering. However, this prior art is mainly used to make hydrogels.
[0007] Through the above explanation of the prior art, those skilled in the art can know that the relevant drugs currently used to treat keratoconus have the following characteristics:
[0008] 1. Most existing technologies are based on riboflavin, which generates singlet oxygen or free radicals by ultraviolet light excitation, and establishes covalent cross-linking bonds between functional groups of amino acid residues on collagen fibers;
[0009] 2. Methods and pharmaceutical compositions for visible light-induced corneal cross-linking using ruthenium compounds, as represented by WO2024054165A1.
[0010] However, these two technologies have the following defects:
[0011] (1) Riboflavin has a very low permeability to the corneal epithelial matrix. During the treatment, the eyes need to be exposed to ultraviolet light for a long time (about 30 minutes in total), which can easily cause irreversible damage to the corneal epithelium and increase the risk of postoperative complications such as corneal edema, permanent corneal opacity, and corneal endothelial failure.
[0012] (2) Although WO2024054165A1 is based on ruthenium compounds and sodium persulfate, the synergistic effect of the two is still small, and the technology does not solve the problem of low permeability to the corneal epithelial mechanism. When used, the corneal epithelium needs to be scraped off, which is prone to cause various postoperative complications such as infection and corneal melting;
[0013] (3) Most existing technologies currently only cross-link corneal collagen and fail to achieve a tighter corneal cross-linking treatment through a double cross-linking mechanism (cross-linking glycoproteins in the corneal stroma and corneal collagen fibers);
[0014] (4) Currently, most existing technologies fail to pay attention to the technical research and development route for preparing virus-like nanoparticles, nor to the use of nanoscale and biological topological structures to promote trans-epithelial efficiency. In addition, they also fail to pay attention to the use of the cations on the surface of virus-like cationic ruthenium-based nanoparticles and the negative charge on the surface of corneal epithelial cells to achieve efficient trans-epithelial penetration into the corneal stroma through adsorption-mediated effects. Summary of the invention
[0015] In view of this, the present invention provides a method for preparing and using virus-like cationic ruthenium-based nanoparticles. The virus-like cationic ruthenium-based nanoparticles utilize their nanoscale and the adsorption-mediated transfer effect between the negative charge on the surface of corneal epithelial cells to efficiently penetrate into the corneal stroma across the epithelium, cross-link with the cornea under visible light catalysis, and achieve non-invasive treatment of keratoconus.
[0016] The virus-like cationic ruthenium nanoparticles provided by the present invention are mainly composed of the following components in mass percentage: 10% to 20% of tricarboxypyridine ruthenium, 40% to 50% of an amino polymer, 40% to 50% of a carboxylated polymer, 1% to 2% of carboxyphenylboronic acid and 1% to 5% of polyvinyl alcohol, and the remaining components are pharmaceutically acceptable carriers. Those skilled in the art can understand that the mass fractions are used here.
[0017] The virus-like cationic ruthenium-based nanoparticles provided by the present invention are mainly prepared by the following steps:
[0018] Step 1: Preparation of cationic ruthenium-based polymers
[0019] The invention is mainly prepared from the following components: ruthenium tricarboxypyridine, an amino polymer, 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS). The EDC and the NHS are mixed to obtain an EDC / NHS mixed solution, and the ruthenium tricarboxypyridine and the amino polymer are added to the EDC / NHS mixed solution to carry out a dehydration condensation reaction to obtain the cationic ruthenium-based polymer.
[0020] Step 2: Preparation of cationic ruthenium-based hollow nanocores
[0021] The invention is mainly prepared from the following components: the cationic ruthenium polymer, the EDC / NHS mixed solution, silica nanoparticles, carboxylation polymer, anhydrous ethanol and 1% hydrofluoric acid solution. Firstly, the cationic ruthenium polymer and the carboxylation polymer are dissolved in anhydrous ethanol to obtain a cationic ruthenium polymer solution and a carboxylation polymer solution respectively; secondly, the silica nanoparticles are dispersed in the cationic ruthenium polymer solution, and the solution is fully stirred and then centrifuged at a speed of ≥12000 rpm to obtain the silica nanoparticles coated with the cationic ruthenium polymer; the silica nanoparticles are placed in the carboxylation polymer solution, and the solution is fully stirred to obtain the silica nanoparticles coated with [carboxylation polymer / cationic ruthenium polymer] 1. particles, repeating the above steps n times and then placing them in the EDC / NHS mixed solution for core-shell crosslinking to obtain [carboxylated polymer / cationic ruthenium polymer]n-coated silica nanoparticles, specifically, n≥3; finally, dispersing the [carboxylated polymer / cationic ruthenium polymer]n-coated silica nanoparticles obtained above in a 1% hydrofluoric acid solution and etching for 10-25 minutes to obtain the cationic ruthenium-based hollow nanocores with silica removed, and collecting them by centrifugation at a speed of ≥12000 rpm.
[0022] Step 3: Preparation of virus-like cationic ruthenium-based nanoparticles
[0023] The invention is mainly prepared from the following components: the cationic ruthenium-based hollow nanocore, the EDC / NHS mixed solution, carboxyphenylboric acid, polyvinyl alcohol and deionized water. The cationic ruthenium-based hollow nanocore and the carboxyphenylboric acid are first placed in the prepared EDC / NHS mixed solution to react for 60-90 minutes to obtain the cationic ruthenium-based hollow nanocore with the surface modified by carboxyphenylboric acid, which is then dispersed in deionized water, and polyvinyl alcohol is added to the solution, and the virus-like cationic ruthenium-based nanoparticles are obtained after stirring for 100-360 minutes.
[0024] In a preferred embodiment of the present invention, the EDC / NHS mixed solution in steps 1 to 3 is prepared by mixing EDC and NHS in a ratio of 7:2, 7:1, 8:1 or 4:1. Those skilled in the art will appreciate that the ratio here is a mass fraction or a volume ratio, preferably a volume ratio.
[0025] In a preferred embodiment of the present invention, the amino polymer includes at least one of polylysine, polyamide, urea and polylactic acid.
[0026] In a preferred embodiment of the present invention, the carboxylated polymer includes at least one of polyvinyl acid, polyacrylic acid, vinyl acrylate copolymer and maleic acid copolymer.
[0027] The present invention provides a method for using virus-like cationic ruthenium-based nanoparticles for treating keratoconus, which also includes 1%-2% ammonium persulfate (those skilled in the art will understand that this is mass fraction or concentration, preferably mass fraction). First, the virus-like cationic ruthenium-based nanoparticles are dispersed in deionized water, and then ammonium persulfate is added to the above solution, and the virus-like cationic ruthenium-based nanoparticle ophthalmic solution is obtained after being fully stirred until the ammonium persulfate is completely dissolved; after dripping the virus-like cationic ruthenium-based nanoparticle ophthalmic solution on the corneal ocular surface for about 30 minutes, it is irradiated with visible light for 5-10 minutes, and repeated 2-5 times, with an interval of 5-10 minutes each time;
[0028] In a preferred embodiment of the present invention, the visible light band ranges from 400 to 650 nm and the intensity is 2 to 5 W / cm2.
[0029] Specifically, after the virus-like cationic ruthenium-based nanoparticle ophthalmic solution is dropped on the ocular surface, it cooperates with the cornea to treat keratoconus through the following two-fold cross-linking mechanism:
[0030] The first cross-linking mechanism is that the cations on the surface of the virus-like cationic ruthenium-based nanoparticles and the negative charge on the surface of the corneal epithelial cells achieve trans-epithelial penetration into the corneal stroma through an adsorption-mediated effect, the polyvinyl alcohol is degraded, the carboxylphenylboronic acid is exposed and contacts the polysaccharide molecules in the corneal stroma, and the glycoproteins in the corneal stroma are cross-linked through boronate ester bonds;
[0031] The second cross-linking mechanism is that under the catalysis of ammonium persulfate and visible light, the cationic ruthenium-based polymer in the virus-like cationic ruthenium-based nanoparticles cross-links corneal collagen fibers through dityrosine groups.
[0032] The present invention also relates to the use of virus-like cationic ruthenium-based nanoparticles in the preparation of ophthalmic preparations;
[0033] Furthermore, the ophthalmic preparation is used to prevent or treat corneal biomechanical property degenerative diseases;
[0034] Furthermore, the ophthalmic solution used only contains virus-like cationic ruthenium-based nanoparticles and pharmaceutically acceptable excipients.
[0035] Further, the ophthalmic preparation is a solution preparation, and the concentration of the virus-like cationic ruthenium-based nanoparticles is 0.8-1.5 mg / mL;
[0036] Furthermore, the pharmaceutically acceptable excipient is one or more selected from an osmotic pressure regulator, a preservative, a solubilizing agent, and a pH regulator; the osmotic pressure regulator is selected from sodium chloride and glucose; the preservative is selected from sodium thimerosal, benzalkonium chloride, benzalkonium bromide, and chlorobutanol; the solubilizing agent is selected from Tween-80 and Tween-20; the pH regulator is selected from sodium hydroxide and hydrochloric acid;
[0037] Further, the concentration of the virus-like cationic ruthenium-based nanoparticles is 0.5-1.0 mg / mL;
[0038] Furthermore, the ophthalmic preparation is 0.3 ml / tube, and is mainly composed of the following components in mass fractions: 1%-2% ammonium sulfate and 30%-60% of the virus-like cationic ruthenium-based nanoparticles. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 is a transmission electron microscopy image of the virus-like cationic ruthenium-based nanoparticles of the present invention;
[0040] Figure 2 The Fourier transform infrared spectra of the tricarboxypyridine ruthenium, the cationic ruthenium-based polymer, the cationic ruthenium-based hollow nanocore and the virus-like cationic ruthenium-based nanoparticles of the present invention are shown;
[0041] Figure 3 Schematic diagram of the virus-like cationic ruthenium-based nanoparticles combined with visible light treatment of the in vitro rabbit cornea of the present invention;
[0042] Figure 4 This is a photo of the virus-like cationic ruthenium-based nanoparticles of the present invention combined with visible light treatment of the in vitro rabbit cornea to resist the degradation of collagen fiber dissolving enzymes;
[0043] Figure 5 This is a bar graph showing the resistance of the virus-like cationic ruthenium-based nanoparticles of the present invention to the degradation of collagen fiber lytic enzymes after the isolated rabbit cornea was treated with visible light;
[0044] In the figure: 1-virus-like cationic ruthenium-based nanoparticle ophthalmic solution, 2-visible light, 3-ex vivo rabbit cornea. DETAILED DESCRIPTION
[0045] The technical scheme of the present invention will be further described in detail below in conjunction with the accompanying drawings and specific implementation cases. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0046] See also Figure 1 The virus-like cationic ruthenium-based nanoparticles provided by the present invention can be used for non-invasive treatment of keratoconus, such as Figure 1 As shown, it is mainly composed of 10% to 20% of tricarboxypyridine ruthenium, 40% to 50% of amino polymer, 40% to 50% of carboxylated polymer, 1% to 2% of carboxyphenylboronic acid, and 1% to 5% of polyvinyl alcohol, and the remaining components are pharmaceutically acceptable carriers. Those skilled in the art can understand that the mass fractions are shown here.
[0047] The virus-like cationic ruthenium-based nanoparticles provided by the present invention are mainly prepared by the following steps:
[0048] Step 1: Preparation of cationic ruthenium-based polymers
[0049] The invention is mainly prepared from the following components: ruthenium tricarboxypyridine, an amino polymer, EDC and NHS. EDC and NHS are mixed to prepare an EDC / NHS mixed solution, and ruthenium tricarboxypyridine and the amino polymer are added to the prepared EDC / NHS mixed solution to carry out a dehydration condensation reaction to prepare a cationic ruthenium-based polymer; Figure 2 Shown are Fourier infrared spectra of tricarboxypyridine ruthenium and cationic ruthenium-based polymers;
[0050] Step 2: Preparation of cationic ruthenium-based hollow nanocores
[0051] The invention is mainly prepared from the following components: cationic ruthenium polymer, EDC / NHS mixed solution, silica nanoparticles, carboxyl polymer, anhydrous ethanol and 1% hydrofluoric acid solution. Firstly, the cationic ruthenium polymer and the carboxyl polymer are dissolved in the anhydrous ethanol to obtain a cationic ruthenium polymer solution and a carboxyl polymer solution respectively; secondly, the silica nanoparticles are dispersed in the cationic ruthenium polymer solution, and the solution is fully stirred and centrifuged at a speed of ≥12000 rpm. The obtained cationic ruthenium polymer-coated silica nanoparticles are placed in the carboxyl polymer solution, and the solution is fully stirred to obtain [carboxyl polymer / cationic ruthenium polymer] 1-coated silica nanoparticles. Repeat the above steps n times and then place in an EDC / NHS mixed solution for core-shell crosslinking to obtain [carboxylated polymer / cationic ruthenium polymer]n coated silica nanoparticles, specifically, n≥3; finally, disperse the [carboxylated polymer / cationic ruthenium polymer]n coated silica nanoparticles obtained above in a 1% hydrofluoric acid solution and etch for 10-25 minutes to obtain cationic ruthenium hollow nanocores with silica removed, and collect by centrifugation at a speed of ≥12000 rpm; Figure 2 Shown is the Fourier infrared spectrum of the prepared cationic ruthenium-based hollow nanocore
[0052] Step 3: Preparation of virus-like cationic ruthenium-based nanoparticles
[0053] It is mainly prepared from the following components: cationic ruthenium-based hollow nanocores, EDC / NHS mixed solution, carboxyphenylboric acid, polyvinyl alcohol and deionized water. First, the cationic ruthenium-based hollow nanocores and carboxyphenylboric acid are placed in the above-prepared EDC / NHS mixed solution to react for 60-90 minutes to obtain cationic ruthenium-based hollow nanocores with surfaces modified by carboxyphenylboric acid; specifically, carboxyphenylboric acid is used to target the corneal stroma and cross-link with glycoproteins in the corneal stroma; then the cationic ruthenium-based hollow nanocores with surfaces modified by carboxyphenylboric acid prepared above are dispersed in deionized water, and polyvinyl alcohol is added to the above solution, and after stirring for 100-360 minutes, virus-like cationic ruthenium-based nanoparticles are obtained, such as Figure 1 Shown is a transmission electron micrograph of the prepared virus-like cationic ruthenium-based nanoparticles, Figure 2 Shown is the Fourier infrared spectrum of the prepared virus-like cationic ruthenium-based nanoparticles;
[0054] Specifically, polyvinyl alcohol is used to wrap the surface of virus-like cationic ruthenium-based nanoparticles to prevent the virus-like cationic ruthenium-based nanoparticles from adhering to the corneal epithelium.
[0055] In a preferred embodiment of the present invention, the EDC and NHS in steps 1 to 3 are mixed in a mass ratio of 7:2, 7:1, 8:1 or 4:1 to prepare an EDC / NHS mixed solution.
[0056] In a preferred embodiment of the present invention, the amino polymer includes at least one of polylysine, polyamide, urea and polylactic acid.
[0057] In a preferred embodiment of the present invention, the carboxylated polymer includes at least one of polyvinyl acid, polyacrylic acid, vinyl acrylate copolymer and maleic acid copolymer.
[0058] The present invention provides a method for using virus-like cationic ruthenium-based nanoparticles for treating keratoconus, which also includes 1%-2% ammonium persulfate. First, the virus-like cationic ruthenium-based nanoparticles are dispersed in deionized water, and then ammonium persulfate is added to the above solution. After fully stirring until the ammonium persulfate is completely dissolved, a virus-like cationic ruthenium-based nanoparticle ophthalmic solution 1 is prepared. After about 30 minutes of dropping the virus-like cationic ruthenium-based nanoparticle ophthalmic solution 1 on the surface of the keratoconus eye, it is irradiated with visible light 2 for 5-10 minutes, and repeated 2-5 times, each time with an interval of 5-10 minutes; specifically, the visible light 2 has a wavelength range of 400-650nm and an intensity of 2-5W / cm2;
[0059] Specifically, after 1 drop of the virus-like cationic ruthenium-based nanoparticle ophthalmic solution is dropped on the ocular surface, it cooperates with the cornea to treat keratoconus through the following two-fold cross-linking mechanism:
[0060] In the first cross-linking mechanism, the cations on the surface of the virus-like cationic ruthenium-based nanoparticles and the negative charge on the surface of the corneal epithelial cells achieve transepithelial penetration into the corneal stroma through an adsorption-mediated effect, polyvinyl alcohol is degraded, and the carboxylphenylboronic acid exposes and releases the polysaccharide molecules in the corneal stroma, and cross-links the glycoproteins in the corneal stroma through boronate ester bonds;
[0061] The second cross-linking mechanism is that under the catalysis of ammonium persulfate and visible light, the cationic ruthenium polymers in the virus-like cationic ruthenium nanoparticles cross-link corneal collagen fibers through dityrosine groups.
[0062] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.
[0063] Example 1 provides a specific preparation example of the virus-like cationic ruthenium-based nanoparticles, which includes the following three steps:
[0064] Step 1: Preparation of cationic ruthenium-based polymers
[0065] EDC and NHS were mixed in a ratio of 7:1 to prepare an EDC / NHS mixed solution, 20 mg of tricarboxypyridine ruthenium and 100 mg of polylysine were added to 20 mL of the EDC / NHS mixed solution prepared above to carry out a dehydration condensation reaction to prepare a cationic ruthenium-based polymer;
[0066] Step 2: Preparation of cationic ruthenium-based hollow nanocores
[0067] 100 mg of cationic ruthenium-based polymer and 100 mg of polyacrylic acid were respectively taken and dissolved in 10 mL of anhydrous ethanol to prepare a cationic ruthenium-based polymer solution and a polyacrylic acid solution;
[0068] 100 mg of silica nanoparticles were dispersed in a cationic ruthenium-based polymer solution, and the solution was stirred thoroughly and then centrifuged at 14,000 rpm. The obtained cationic ruthenium-based polymer-coated silica nanoparticles were placed in the polyacrylic acid solution, and stirred thoroughly to obtain [polyacrylic acid / cationic ruthenium-based polymer] 1-coated silica nanoparticles. The above steps were repeated 3 times, and the silica nanoparticles were placed in the EDC / NHS mixed solution for core-shell crosslinking to obtain [polyacrylic acid / cationic ruthenium-based polymer] 3-coated silica nanoparticles.
[0069] The silica nanoparticles coated with the [polyacrylic acid / cationic ruthenium-based polymer] 3 prepared above were dispersed in 20 mL of 1% hydrofluoric acid solution for 20 minutes of etching reaction, and centrifuged at 14,000 rpm to obtain cationic ruthenium-based hollow nanocores with silica removed;
[0070] Step 3: Preparation of virus-like cationic ruthenium-based nanoparticles
[0071] 10 mg of the cationic ruthenium-based hollow nanocores prepared in step 2 and 100 mg of carboxyphenylboronic acid were placed in an EDC / NHS mixed solution and reacted for 60 minutes to obtain cationic ruthenium-based hollow nanocores with surfaces modified by carboxyphenylboronic acid;
[0072] The cationic ruthenium-based hollow nanocores with surfaces modified with carboxylphenylboronic acid prepared above were dispersed in 50 mL of deionized water, and 100 mg of polyvinyl alcohol was added to the above solution. After stirring for 120 minutes, virus-like cationic ruthenium-based nanoparticles were obtained.
[0073] Example 2 provides a specific preparation example of the virus-like cationic ruthenium-based nanoparticles, which includes the following three steps:
[0074] Step 1: Preparation of cationic ruthenium-based polymers
[0075] EDC and NHS are mixed in a ratio of 4:1 to prepare an EDC / NHS mixed solution, 15 mg of tricarboxypyridine ruthenium and 50 mg of urea are added to the prepared EDC / NHS mixed solution to carry out a dehydration condensation reaction to prepare a cationic ruthenium-based polymer;
[0076] Step 2: Preparation of cationic ruthenium-based hollow nanocores
[0077] 50 mg of cationic ruthenium-based polymer and 40 mg of maleic acid copolymer were respectively taken and dissolved in 5 mL of anhydrous ethanol to prepare a cationic ruthenium-based polymer solution and a maleic acid copolymer solution;
[0078] 50 mg of silica nanoparticles are dispersed in the cationic ruthenium-based polymer solution, stirred thoroughly and then centrifuged at 15,000 rpm, the obtained cationic ruthenium-based polymer-coated silica nanoparticles are placed in the maleic acid copolymer solution, stirred thoroughly to obtain [maleic acid copolymer / cationic ruthenium-based polymer] 1-coated silica nanoparticles, the above steps are repeated 5 times and then placed in the EDC / NHS mixed solution for core-shell crosslinking to obtain [maleic acid copolymer / cationic ruthenium-based polymer] 5-coated silica nanoparticles;
[0079] The silica nanoparticles coated with the [maleic acid copolymer / cationic ruthenium-based polymer] 5 prepared above were dispersed in 10 mL of 1% hydrofluoric acid solution and etched for 20 minutes, and collected by centrifugation at a speed of 15,000 rpm to obtain cationic ruthenium-based hollow nanocores with silica removed;
[0080] Step 3: Preparation of virus-like cationic ruthenium-based nanoparticles
[0081] 10 mg of the cationic ruthenium-based hollow nanocores prepared in step 2 and 100 mg of carboxyphenylboronic acid were placed in an EDC / NHS mixed solution and reacted for 90 minutes to obtain cationic ruthenium-based hollow nanocores with surfaces modified by carboxyphenylboronic acid;
[0082] The cationic ruthenium-based hollow nanocores with surfaces modified by carboxylphenylboronic acid prepared above were dispersed in deionized water, and 200 mg of polyvinyl alcohol was added to the above solution. After stirring for 180 minutes, virus-like cationic ruthenium-based nanoparticles were obtained.
[0083] Example 3 provides a specific use method and treatment situation of the virus-like cationic ruthenium-based nanoparticles combined with visible light 2-mediated treatment of ex vivo rabbit cornea 3:
[0084] Weigh 1 mg of virus-like cationic ruthenium-based nanoparticles and put them into 1 mL of deionized water. Place them in an ultrasonic cleaner for ultrasonic dispersion for 360 seconds, then add 10 μg of ammonium persulfate and stir until the ammonium persulfate is completely dissolved to prepare virus-like cationic ruthenium-based nanoparticle ophthalmic solution 1. Incubate at room temperature for 30 minutes. Figure 3 As shown, 300 μL of the ophthalmic solution was drawn with a dropper each time and dropped dropwise onto the ocular surface of the isolated rabbit cornea 3 for 30 minutes, and then irradiated with 480 nm visible light 2 at an intensity of 3 W / cm2 for 10 minutes, and repeated 3 times, with an interval of 10 minutes each time. In order to evaluate the treatment of the isolated rabbit cornea 3 by the virus-like cationic ruthenium-based nanoparticles, the isolated rabbit cornea 3 treated with the virus-like cationic ruthenium-based nanoparticles was immersed in 20 mL of 0.1% collagen fiber dissolving enzyme solution, as shown in FIG. Figure 4 and Figure 5 As shown, the isolated rabbit cornea 3 treated with virus-like cationic ruthenium-based nanoparticles combined with visible light 2 was able to resist the degradation of collagen fiber lytic enzymes and still retained 50% of the cornea after 12 hours.
[0085] Comparative Example 1 provides a treatment situation of deionized water combined with visible light 2 to treat the isolated rabbit cornea 3:
[0086] Take 1mL of deionized water and incubate at room temperature for 30 minutes. Use a dropper to draw 300μL of deionized water solution each time and drop it drop by drop on the surface of the isolated rabbit cornea 3. After 30 minutes, irradiate with 480nm visible light 2 with an intensity of 3W / cm2 for 10 minutes. Repeat 3 times, with an interval of 10 minutes each time. Put the isolated rabbit cornea 3 treated with deionized water and visible light 2 into 20mL of 0.1% collagen fiber dissolving enzyme solution, as shown in Figure 4 and Figure 5 As shown, the in vitro rabbit cornea 3 treated with deionized water combined with visible light 2 was completely degraded after 12 hours.
[0087] Comparative Example 2 provides the treatment of isolated rabbit cornea 3 using riboflavin combined with ultraviolet light:
[0088] Take 1 mg of riboflavin molecules and dissolve them in 1 mL of deionized water to prepare a riboflavin ophthalmic solution. Incubate at room temperature for 30 minutes. Use a dropper to draw 300 μL of riboflavin ophthalmic solution each time and drop it drop by drop on the surface of the isolated rabbit cornea 3. After 30 minutes, irradiate with 365 nm ultraviolet light at an intensity of 3 W / cm2 for 10 minutes. Repeat 3 times with an interval of 10 minutes each time. Put the isolated rabbit cornea 3 treated with riboflavin molecules combined with ultraviolet light intervention into 20 mL of 0.1% collagen fiber dissolving enzyme solution. Figure 4 and Figure 5 As shown, the in vitro rabbit cornea 3 treated with riboflavin molecules combined with ultraviolet light intervention was completely degraded after 12 hours.
[0089] In addition, it is clear to those skilled in the art that the various components in the present invention are either mass fractions or volume fractions, and the other unmentioned components are pharmaceutically acceptable components or excipients, which will not be described in detail here. Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention is described in detail with reference to the aforementioned embodiments, it should be understood by those skilled in the art that the technical solutions described in the aforementioned embodiments can still be modified, or some or all of the technical features therein can be replaced by equivalents; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A virus-like cationic ruthenium-based nanoparticle, characterized in that: The invention comprises 10% to 20% of tricarboxypyridine ruthenium, 40% to 50% of amino polymer, 40% to 50% of carboxy polymer, 1% to 2% of carboxyphenylboric acid, and 1% to 5% of polyvinyl alcohol.
2. A method for preparing virus-like cationic ruthenium-based nanoparticles as claimed in claim 1, characterized in that: The steps include: Step 1 is to prepare a cationic ruthenium-based polymer, wherein the raw materials used in the preparation include tricarboxypyridine ruthenium, an amino polymer, EDC and NHS; the EDC and the NHS are mixed to prepare an EDC / NHS mixed solution, and the tricarboxypyridine ruthenium and the amino polymer are added to the prepared EDC / NHS mixed solution to carry out a dehydration condensation reaction to prepare a cationic ruthenium-based polymer; Step 2 is to prepare cationic ruthenium-based hollow nanocores. The raw materials used in the preparation include the cationic ruthenium-based polymer prepared in step 1, silica nanoparticles, carboxylated polymer, anhydrous ethanol, EDC / NHS mixed solution and 1% hydrofluoric acid solution; firstly, the cationic ruthenium-based polymer and the carboxylated polymer prepared in step 1 are dissolved in anhydrous ethanol to prepare a cationic ruthenium polymer solution and a carboxylated polymer solution respectively; secondly, the silica nanoparticles are first placed in the cationic ruthenium-based polymer solution obtained in step 1, and the silica nanoparticles coated with the cationic ruthenium polymer are obtained after sufficient stirring; and the cationic ruthenium polymer is centrifuged at a speed of ≥12000 rpm to collect the cationic ruthenium polymer. The silica nanoparticles coated with the compound are placed into the carboxylated polymer solution obtained above, and after being fully stirred, the silica nanoparticles coated with [carboxylated polymer / cationic ruthenium polymer] 1 are obtained, and the above steps are repeated for n≥3 times, and then placed in an EDC / NHS mixed solution for core-shell crosslinking to obtain silica nanoparticles coated with [carboxylated polymer / cationic ruthenium polymer] n; finally, the silica nanoparticles coated with [carboxylated polymer / cationic ruthenium polymer] n obtained above are dispersed in a 1% hydrofluoric acid solution for an etching reaction for 10-25 minutes, and then centrifuged at a speed of ≥12000 rpm to obtain cationic ruthenium hollow nanocores; Step three is to prepare virus-like cationic ruthenium-based nanoparticles. The raw materials used in the preparation include the cationic ruthenium-based hollow nanocores prepared in step two, carboxylphenylboric acid, EDC / NHS mixed solution, polyvinyl alcohol and deionized water; the cationic ruthenium-based hollow nanocores prepared in step two and the carboxylphenylboric acid are placed in the EDC / NHS mixed solution for reaction for 60-90 minutes to obtain cationic ruthenium-based hollow nanocores with surfaces modified by carboxylphenylboric acid; finally, polyvinyl alcohol is added to the above solution, and the virus-like cationic ruthenium-based nanoparticles are obtained after stirring for 100-360 minutes.
3. The method for preparing virus-like cationic ruthenium-based nanoparticles according to claim 2, characterized in that: The EDC / NHS mixed solution is prepared by mixing the EDC and NHS in a ratio of 7:2, 7:1, 8:1 or 4:
1.
4. The method for preparing virus-like cationic ruthenium-based nanoparticles according to claim 2, characterized in that: The amino polymer includes at least one of polylysine, polyamide, urea and polylactic acid.
5. The method for preparing virus-like cationic ruthenium-based nanoparticles according to claim 2, characterized in that: The carboxylated polymer includes at least one of polyvinyl acid, polyacrylic acid, vinyl acrylate copolymer and maleic acid copolymer; The method of use also includes using 1%-2% ammonium persulfate; first dispersing the virus-like cationic ruthenium-based nanoparticles in the deionized water, then adding ammonium persulfate to the above solution, stirring until the ammonium persulfate is completely dissolved to obtain a virus-like cationic ruthenium-based nanoparticle ophthalmic solution, dripping the virus-like cationic ruthenium-based nanoparticle ophthalmic solution on the keratoconus eye surface for about 30 minutes, irradiating with visible light for 5-10 minutes, repeating 2-5 times, each time with an interval of 5-10 minutes; The visible light band ranges from 400-650nm, and the intensity is 2-5W / cm2; After the virus-like cationic ruthenium-based nanoparticles are dropped on the ocular surface, they are catalyzed by visible light through a first-layer cross-linking mechanism with glycoproteins in the corneal stroma and a second-layer cross-linking mechanism with corneal collagen fibers; The first-layer cross-linking mechanism with glycoproteins in the corneal stroma includes that the cations on the surface of the virus-like cationic ruthenium-based nanoparticles and the negative charge on the surface of the corneal epithelial cells achieve trans-epithelial penetration into the corneal stroma through an adsorption-mediated effect, the polyvinyl alcohol is degraded, and the carboxyphenylboronic acid contacts and cross-links with glycoproteins in the corneal stroma through boronate bonds.
6. The method for using the virus-like cationic ruthenium-based nanoparticles according to claim 5, characterized in that: The second cross-linking mechanism of tyrosine groups in cross-linked collagen fibers includes cross-linking of the cationic ruthenium-based polymer with corneal collagen fibers through dityrosine groups under the catalysis of ammonium persulfate and visible light.
7. Use of the virus-like cationic ruthenium-based nanoparticles as claimed in claim 1 in the treatment of keratoconus.
8. Use of the virus-like cationic ruthenium-based nanoparticles according to any one of claims 5 to 6 in the treatment of keratoconus.
9. Use of virus-like cationic ruthenium-based nanoparticles in the preparation of ophthalmic preparations.
10. The use according to claim 9, wherein the ophthalmic preparation is used for preventing or treating corneal biomechanical property degenerative diseases.
Citation Information
Patent Citations
Use of enhancers that can be used with riboflavin in the preparation of ophthalmic compositions for corneal cross-linking in the treatment of keratoconus, and the corresponding ophthalmic compositions.
CN102164592B
Ophthalmic solution for protecting internal structures fo the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique
CN102470120A
Application of adrenaline receptor agonists in the preparation of cross-linking permeation enhancers for keratoconus
CN115177729B
Light-activated preparation of hydrogels
WO2017095240A1
A method and a pharmaceutical composition for visible light-induced corneal crosslinking with ruthenium compounds for the treatment of eye disorders
WO2024054165A1
